Life expectancy while taking dasatinib

Dasatinib (Dasatinib), as a targeted therapy, has shown significant survival prolongation effects in clinical trials. Studies on patients with chronic myelogenous leukemia (CML) and partially drug-resistant chronic myelogenous leukemia have shown that the use of dasatinib (Startaxed) can significantly improve the survival and quality of life of patients.

In CMLpatients, the results of multiple clinical trials have shown that dasatinib can significantly prolong the patient's progression-free survival (Progression-Free Survival, PFS), that is, the time during which the patient does not experience disease progression during treatment. A long-term follow-up study on CML patients found that the 5 year progression-free survival rate of the dasatinib (Stardas) treatment group reached 80% and had obvious advantages over the traditional treatment group.

In addition, the therapeutic effect of dasatinib (Shidasel) has also been verified in patients with partially drug-resistant CML and Ph+ ALL. Clinical trial results show that dasatinib can effectively control disease progression and prolong patient survival. For patients with Ph+ ALL, the use of dasatinib (Startax) provides them with an important treatment option and improves the patient's survival prospects.

Although dasatinib has shown good survival prolongation effects in treatment, the patient's physical condition still needs to be closely monitored during use and adjustments made as necessary. In addition, patients should follow the doctor's recommendations and undergo regular examinations and follow-up visits to ensure the best treatment effect and quality of life.

To sum up, dasatinib (Dasatinib), as a targeted therapy, has proven its significant effect in prolonging the survival of patients in clinical trials. For patients with CML and partially drug-resistant CML, Ph+ ALL, the use of dasatinib (Startaxed) provides them with an effective treatment option, bringing better survival prospects and quality of life.